Share this article and save a life!
The FDA just changed drug development forever.
For the first time, an AI pathology tool has been officially qualified to assess liver disease in clinical trials. This isn’t another radiology approval, this is AI directly influencing how new drugs get tested and approved.
Here’s why this matters:
MASH (metabolic dysfunction-associated steatohepatitis) affects 115 million Americans. Until now, drug trials required human pathologists to manually score thousands of liver biopsies, creating massive bottlenecks and subjective variability.
The qualified AI tool can now:
✓ Standardize disease assessment across trials
✓ Accelerate patient enrollment
✓ Reduce inter-reader variability
✓ Cut drug development timelines
But here’s what’s fascinating:
While we’ve seen 1,000+ AI tools approved for clinical diagnosis, this is the first qualified specifically for pharmaceutical development under the 21st Century Cures framework.
This sets a precedent. If AI can assess liver disease for drug trials, what about:
• Tumor response in oncology trials?
• Neurodegeneration in Alzheimer’s studies?
• Cardiac function in heart failure research?
The implications are staggering. Clinical trials consume 60% of drug development costs. If AI can standardize and accelerate trial endpoints, we’re looking at faster drug approvals and lower costs.
Yet questions remain:
Will pharmaceutical companies trust AI over human pathologists for billion-dollar decisions? How will this affect trial site selection when AI can analyze samples remotely? What happens when AI and human assessments disagree?
One thing is clear: The FDA isn’t just approving AI anymore, they’re integrating it into the fabric of drug development.
This qualification signals a new era where AI doesn’t just diagnose disease, it helps create the cures.
The pharmaceutical industry just got its first AI co-pilot. The question isn’t whether others will follow, but how quickly.
♻️ Repost if AI should accelerate life-saving drug development
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
